0000000000000000002179008

First Page		Document Content
Date: 2014-10-10 11:08:31 Gilead Sciences Specialty drugs Breakthrough therapy Ledipasvir/sofosbuvir Cyclopropanes Sofosbuvir Ledipasvir Gilead		0000000000000000002179008 Add to Reading List Source URL: www.gilead.com Download Document from Source Website File Size: 94,92 KB Share Document on Facebook

	1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni DocID: 1t14c - View Document
	Microsoft Word - GILEAD BRIEFING DocID: 1r2Vm - View Document
	--------------------------------CONTRAINDICATIONS----------------------------- EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN DocID: 1qjt9 - View Document
	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl DocID: 1qgyA - View Document
	Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction DocID: 1pRH9 - View Document